Novavax, Inc.
Novavax, Inc. develops vaccines to combat serious infectious diseases using a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant. The company focuses on urgent health challenges like COVID-19, influenza, and malaria. It commercializes a COVID-19 vaccine for adult and adolescent populations as well as booster indications. Novavax also develops an R21/Matrix-M adjuvant malaria vaccine.
Overview
Strengths
- Current Price to Earnings Ratio (2.94) is lower than the sector mean (91.15).
- EV/EBITDA (2.11) is lower than the sector mean (85.60).
- EV/EBIT (2.81) is lower than the sector mean.
- Strong EBITDA Margin of 55.09%.
Weaknesses
- With a depreciation Potential of -100.00%, based on our fundamental analysis, it suggests the stock may be overvalued.
- Price to book ratio (100.00) is significantly higher than the sector mean (24.44).
- Analysts expect revenues to decline in the coming year.
- The company have lower returns than the sector in which it operates. ROIC (0.00%) is significantly lower than the sector mean (6.02%).
Key Financial Data